



MASTERING
MEDICINES
DEVELOPMENT



Eudipharm



www.eudipharm.net


Eudipharm



Université Claude Bernard  Lyon 1

Eudipharm is part of a consortium called PharmaTrain (22 European universities), which aims to harmonize Masters of Pharmaceutical Medicine in Europe. Our program is based on the PharmaTrain syllabus and leads to a Master in Medicines Development (MMD).

*
MASTERING
MEDICINES
DEVELOPMENT

PHARMACEUTICAL MEDICINE, A NEW SPECIALTY

- Defined by the International Federation of Physicians of the Pharmaceutical Industry as

"... a medical and scientific speciality concerned with, for the best of patients, the discovery, development, evaluation and monitoring of Medicines for Human Use and Medical aspects of their marketing"

(after a document entitled: Education in Pharmaceutical Medicine, 1st Report of the IFAPP Working Party, Stockholm, June 1996).

- Medicines should be viewed in this definition in broader meaning than just drugs. They include all type of interventions based on an industrial product.
- Subsequently, Pharmaceutical Medicine differs from: Clinical Pharmacy, Therapeutics, Clinical Pharmacology, Public Health Medicine, even if it borrows from all these disciplines.

AN UP-TO-DATE SCIENTIFIC TRAINING CARRIES NEW OPPORTUNITIES IN THE HEALTH INDUSTRY.

The pharmaceutical industry is becoming more and more international.

- Globalization and harmonization of regulatory requirements (ICH) for medicinal products between developed countries has progressively led to the pre-clinical and clinical development of drugs worldwide. This has resulted in complex integrated development and registration strategies. The health industry can offer key positions, as soon as students acquire needed skills in pharmaceutical medicine.





MASTER IN MEDICINES DEVELOPMENT (MMD)

- 1st year of the *Eudipharm* program which includes six modules, that are in line with the International Federation of Associations of Pharmaceutical Physicians (IFAPP) syllabus. All courses are taught in English and an Intensive English course is offered.
- Students must complete a six-month internship aimed at preparing them to become professionals in the healthcare industry, CROs, regulatory bodies, to work as faculty, researchers in higher education institutions, as principal investigators in private or public practice.
- The University Diploma (the 2nd year of *Eudipharm*) is open to Master degree graduated students. They must attend the four extension modules and at least two elective modules to obtain the diploma. The choice of “À la carte” Elective Modules (from two to six days) is proposed to fit in with the needs of industry, CRO, and agency executives. The aim is to provide continuing professional development for those wishing to update their knowledge or to acquire new expertise through the continuing pharmaceutical medicine education program.

IMI / PHARMATRRAIN COURSES

- We are an official partner of the European IMI PharmaTrain project and have adapted our curriculum to the new shared standards of PharmaTrain. PharmaTrain is one of the IMI JU projects on Education and Training and addresses Pharmaceutical Medicine / Drug Development Sciences. IMI stands for Innovative Medicines Initiative, a Joint Undertaking of the European Commission and European Federation of Pharmaceutical Industries and Associations, EFPIA. Consult www.pharmatrain.eu & www.imi.europa.eu



MODULES

Base modules

- Introductory Module, Principles of Discovery of Medicine and Development Planning
- Non-Clinical Testing, Pharmaceutical and Early Clinical Development
- Exploratory and Confirmatory Clinical Development
- Clinical Trials
- Regulatory Affairs; Drug Safety & Pharmacovigilance
- Healthcare Marketplace; Economics of Healthcare


Extension modules

- Biologicals
- Special Populations Trial Practice
- Pharmacovigilance-ology Drug Safety Surveillance
- Pharmacoeconomics Markets
- 2 Elective Modules

"A LA CARTE"

Elective modules

- Biomarkers & Surrogate Endpoints
- Clinical Project Management
- Drug Development in Children
- Drug Evaluation in Rare Diseases
- Ethics & Legal Issues
- Generics & Biosimilars
- Geriatrics
- Medicine Regulation
- Meta-Analysis
- Modeling & Simulation
- Pregnancy & Medications



Base modules

- Introductory Module, Principles of Discovery of Medicine and Development Planning
- Non-Clinical Testing, Pharmaceutical and Early Clinical Development
- Exploratory and Confirmatory Clinical Development
- Clinical Trials
- Regulatory Affairs; Drug Safety & Pharmacovigilance
- Healthcare Marketplace; Economics of Healthcare



Extension modules

- Biologicals
- Special Populations Trial Practice
- Pharmacoevidence-miology Drug Safety Surveillance
- Pharmacoeconomics Markets
- 2 Elective Modules

COURSE ORGANIZATION

- Teaching takes place in Lyon (where accommodation is available for medium duration stay to students and teachers), and in other participating institutions. Some extension modules will be taught at Semmelweis University in Budapest and the Free University of Brussels.

Courses are given in English.

Teaching is inter-active and practical. All courses are available on the *Eudipharm* website. Basic education and continuing education students learn together. Teaching is based on personal work, and an extensive use of pre and post-testing. It includes repeated assessment of students through multiple-choice questions, oral presentations and case studies. Presentations of case studies are regularly given by students. These presentations are marked as part of the continuing evaluation process.

Each student is supervised by a tutor. The tutor assigned to each student will usually be a faculty member, but he/she could be from outside the diploma staff. In the latter instance, the proposed tutor should demonstrate a marked interest in and commitment to the diploma, its objectives, and procedures. The tutor is appointed by the Academic Committee. The tutor is the permanent contact person for the student and helps him/her to solve problems related to training and pedagogy. He/she is the advisor for activities dealing with scientific bibliography and literature. He/she will advise on the choice of a dissertation topic and in the search for a practical training.






ABOUT THE STUDENTS


Who can apply to Eudipharm?

- Basic training is organised for doctors, post-graduate students, or students following their residency, with a background in human medicine, dentistry, veterinary medicine, and/or pharmacy. Candidates for the diploma must have a background in pharmacology and methodology in clinical research, and a good command of the English language. Continuing education is aimed at physicians, pharmacists, dentists, veterinarians, or other scientists, with current or past positions in research, development, registration, evaluation, and post-marketing monitoring of medicines. Grants can be offered to students via ASFODEMP (see “Practical Information”)

Where do the students come from?



Where do graduates work now?



FOUNDERS

Jean-Pierre Boissel
Françoise Dürr
John Gueriguan
Jean-Marc Husson



COORDINATING COMMITTEE

Séverine Clamaron · AS
Behrouz Kassaï · MD, PhD
Kent Neal · MSc


ABOUT THE TEACHERS

Leon Aarons · BSc, MSc, PhD: University of Manchester, UK
Thierry Barsalou · MD, PhD: Ipsen, F
Rolf Bass · MD, PhD, FFPM: BfArM, G
Gerd Bode · MD, PhD: Altanapharma, Goettingen, G
François-Henri Boissel · MBA: Novadiscovery, F
Jean-Pierre Boissel · MD, PhD: Prof. Emeritus UCLB, F
Michael Bone · BSc, MB, DCH, FRCP: South Tyneside NHS Foundation Trust, UK
Marie-Claude Bonnet · MD: Sanofi-Pasteur, F
Roselyne Bouliou · MD, PhD: Claude Bernard University, F
Giampiero Bricca · MD, PhD: Claude Bernard University, F
Catherine Brun-Strang · MD, PhD: Sanofi-Aventis
Pierre Chatelain · MD: Claude Bernard University, F

Patrick Chevarier · PhD: ClinInfo, F
Ton Cleophas · MD, PhD: A. Schweizer Hospital, Dordrecht, NL
Catherine Cornu · MD: Clinical Investigation Center (HCL), F
Jacques Descotes · MD, PharmD, PhD: Pharmacovigilance Center (HCL), F
Dominique Dubois · MD, KUL, FFPM, FBCPM: PVS Consultancy, B
Ségolène Gaillard · MSc: Clinical Investigation Center (HCL), F
Erick Gaussens · PhD: Product Life, F
Tiphanie Ginhoux · MSc: Clinical Investigation Center (HCL), F
Pascal Girard · PhD: Claude Bernard University, F
Fouzia Guenaneche · MD, PhD: on sabbatical leave, Lyon, F
John Gueriguan · MD: PharmaGenesis, USA
Margaret Haugh · PhD: MediComConsult, F
Youssef Hijazi · PhD: Actelion, Basel, CH
Judith K Jones · MD, PhD: The Degge Group Ltd, Arlington USA
Behrouz Kassaï · MD, PhD: Claude Bernard University Lyon1, F
Sandor Kerpel-Fronius · MD, DSc: Dept. of Pharmacy & Pharmacotherapy, Semmelweis Univ., Budapest, H
Alexandre Kiazand · MD, Boehringer-Ingelheim, USA
Peter-Jürgen Kramer · MD, PhD: Merck Serono Research, G
Laurent Laforest · MD, PhD: Claude Bernard University, F
Christian Laveille · PharmD: Exprimio, F
Alain Leizorovicz · MD, PharmD: Inserm, F
Michel Lièvre · DVM, PhD: Claude Bernard University Lyon1, F
Pierre Mallia · MD, MPhil, MA(law), PhD: University of Malta, Medical Council, M
Christine Marey · MD: Servier, F
Lyn Morgan · MD: Sanofi-Pasteur, F
Patrice Nony · MD, PhD: Claude Bernard University Lyon1, F
Klaus Olejniczak · DVM: Federal Institute for Drugs and medical Devices, G
Yannick Pletan · MD, MSc, FFPM: Pfizer, F
Beatriz Silva Lima · PharmD, PhD: University of Lisboa, P
Hans Martin Spath · PharmD, PhD: Claude Bernard University ISPB, F
Delphine Teppe · MSc: Hospices Civils de Lyon, F
Eric Van Ganse · MD, PhD: Claude Bernard University, F
Thierry Vial · MD: Center of Pharmacovigilance (HCL), F
Aeilko Zwinderman · PhD: University of Amsterdam, NL

EUROPEAN TRAINING

Brussels, Pharmed · www.ulb.ac.be/medecine/pharmed
Karolinska · www.karolinska.se
Basel, ECPM · www.ecpm.ch
Budapest · <http://gyogyszerfejlesztés.hu>
University of Barcelona · www.uab.es
Lyon, Eudipharm · www.eudipharm.net
Belgrade · www.med.bg.ac.rs
Cardiff · www.cardiff.ac.uk
Duisburg-Essen · www.pme-institute.com
Hibernia College · www.hiberniacollege.net
King's College London · www.kcl.ac.uk
Milano · www.masterfarmaco.medicina.unimib.it
Rome · www.rm.unicatt.it/master
Surrey · www.surrey.ac.uk/postgraduate
Trinity, Dublin · www.pac.ie/tcd
Newcastle · www.ncl.ac.uk/biomedicine/postgrad/
Vienna/VSCR · www.vscr.at



EUDIPHARM & PHARMATRAIN

- The main objective of the PharmaTrain (Pharmaceutical Medicines Training Programme) project is to build and implement a new modular Master's level programme for advanced studies in pharmaceutical medicine and drug development sciences. The programme is based on the Bologna credit and title system and builds on the new PharmaTrain Syllabus 2010. The modular concept of the training programme also provides an opportunity for professionals to select courses for accredited Continued Professional Development (CPD), as well as individualized training à la carte. The PharmaTrain consortium has identified six base courses and 13 master level programmes at European universities that will be harmonized at a high-quality level. *Eudipharm* is part of this programme.
- PharmaTrain will set, maintain and constantly improve the standards and quality management of the training schemes and practices for professionals working in drug development. The programme will encourage exchanges between industry, regulators, and academia, produce and promote distance e-learning programmes, and will enable increased flexibility, transferability and mobility. By providing a chart of available and planned training programmes at different levels across Europe, PharmaTrain will identify regions with unmet needs and plan the pan-European expansion accordingly.

For more information about PharmaTrain, visit: www.pharmatrain.eu





CONTACT

Eudipharm
Faculté de médecine Laennec

7, rue Guillaume Paradin
69376 Lyon cedex 08
France

Tel.: +33 (0)4 78 78 57 55
Fax: +33 (0)4 78 77 69 17

PRACTICAL INFORMATION

ASFODEMP

Association for Pharmaceutical Medicine Training, Development and Teaching

- ASFODEMP aims to offer grants to students enabling them to attend this training programme on pharmaceutical medicine. Grants are given based on students financial need. For more information about ASFODEMP, please call +33 (0)4 78 78 57 55 or visit the *Eudipharm* website at www.eudipharm.net

How to register?

Download the application file on *Eudipharm* website:
<http://www.eudipharm.net/claroline141/REG01/>

For further information, please contact Séverine Clamaron at:
sc@upcl@univ-lyon1.fr or +33 (0)4 78 78 57 55

Registration fees

For cost information, please visit our website: <http://www.eudipharm.net>





www.eudipharma.net
Eudipharma



Base Modules

- Learning & Confirming Trials: Finding & Confirming the Right Dose
- Confirming Trials: Methodology & Biostatistics
- The Global Registration & Market Approval Process
- Integrated Product Development, Portfolio Management, & Marketing
- Global Drug Development & Pharmaceutical Business Environment
- From Preclinical Testing to Proof of Concept in Humans

MASTER IN MEDICINES DEVELOPMENT (MMD)

• 1st year of the *Eudipharm* program which includes six modules, that are in line with the International Federation of Associations of Pharmaceutical Physicians (IFAPP) syllabus. All courses are taught in English and an Intensive English course is offered.

• Students must complete a six-month internship aimed at preparing them to become professionals in the healthcare industry, CROs, regulatory bodies, to work as faculty, researchers in higher education institutions, as principal investigators in private or public practice.

• The University Diploma (the 2nd year of *Eudipharm*) is open to Master degree graduated students. They must attend the four extension modules and at least two elective modules to obtain the diploma. The choice of “À la carte” Elective Modules (from two to six days) is proposed to fit in with the needs of industry, CRO, and agency executives. The aim is to provide continuing professional development for those wishing to update their knowledge or to acquire new expertise through the continuing pharmaceutical medicine education program.

“A LA CARTE”

Elective modules

- Biomarkers & Surrogate Endpoints
- Clinical Project Management
- Drug Development in Children
- Drug Evaluation in Rare Diseases
- Ethics & Legal Issues
- Generics & Biosimilars
- Geriatrics
- Medicine Regulation
- Meta-Analysis
- Modeling & Simulation
- Pregnancy & Medications

IMI / PHARMATRRAIN COURSES



• We are an official partner of the European IMI PharmaTrain project and adapt our training activity to the new shared standards of PharmaTrain. PharmaTrain is one of the IMI JU projects on Education and Training and addresses Pharmaceutical Medicine / Drug Development Sciences. IMI stands for Innovative Medicines Initiative, a Joint Undertaking of the European Commission and European Federation of Pharmaceutical Industries and Associations, EFPIA. Consult www.pharmatrain.eu & www.imi.europa.eu

MODULES

Base modules

- The Global Registration and Market Approval Process
- Confirming Trials: Methodology and Biostatistics
- Integrated Product Development, Portfolio Management and Marketing
- From Preclinical Testing to Proof of Concept in Humans
- Global Drug Development and Pharmaceutical Business Environment
- Learning and Confirming Trials: Finding and Confirming the Right Dose

Extension modules

- Biologicals
- Special Populations Trial Practice
- Pharmacovigilance Drug Safety Surveillance
- Pharmacoeconomics Markets
- 2 Elective Modules

